Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts’ expectations for revenues. Shares of the biopharmaceutical company dropped almost …
Nektar Therapeutics (NKTR) presented some updated results on Friday, November 9th from the melanoma expansion cohort of Phase II from PIVOT-02 study. The cancer-focused …
Mizuho’s Difei Yang offers a bullish take on NKTR stock in a week that saw Wall Street running for the hills on the drug maker.
Esperion Therapeutics Inc (NASDAQ:ESPR) and Nektar Therapeutics (NASDAQ:NKTR) are skyrocketing with a fury today on back of major clinical strides forward that have investors …
Nektar Therapeutics (NASDAQ:NKTR) reported its financial results for the second quarter ended June 30, 2015. Cash and investments in marketable securities at June 30, …
Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved …
Isis Pharmaceuticals It can be very difficult to find companies that are both flying under the radar, and still might have potential for …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Nektar Therapeutics (NASDAQ:NKTR) Thursday, maintaining a Buy rating on the stock with …
Nektar Therapeutics (NASDAQ:NKTR) and The University of Texas MD Anderson Cancer Center announced a research collaboration that includes a Phase 1/2 clinical study …
Nektar Therapeutics (NASDAQ:NKTR) reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan’s Ministry …
